Filing Flows › Ginkgo Bioworks Holdings (DNA) › Q3 2026
Ginkgo Bioworks Holdings (DNA) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 9, 2026
Ginkgo Bioworks Holdings (DNA) reported revenue of $27.7M for the third quarter 2026 (Q3 2026), -6% from a year earlier and +37% from the quarter before. Operating margin was -157.5%, net loss $41.0M (147.9% of revenue).
Ginkgo Bioworks Holdings, Q3 2026: revenue $27.7M (-6% year over year), operating margin -157.5%, net loss $41.0M, operating cash flow −$28.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $27.7M | +37% | -6% |
| Operating profit | −$43.6M | — | — |
| Net earnings | −$41.0M | — | — |
| Operating cash flow | −$28.3M | — | — |
What changed
Revenue was $27.7M in Q3 2026, down 6% year over year and up 37% from the previous quarter.
Operating costs exceeded revenue by $43.6M, an operating margin of -157.5%. Total costs fell 36% while revenue fell 6%. The quarter ended with a net loss of $41.0M, narrower than the previous quarter's $46.7M loss.
Operating cash flow was −$28.3M. Non-cash charges added back $12.0M of depreciation and amortization and $7.7M of share-based compensation. Working capital and other items used $7.1M. Capital expenditures of $2.0M exceeded it, leaving free cash flow of −$30.3M.
Questions
What was Ginkgo Bioworks Holdings' revenue in the third quarter 2026?
Ginkgo Bioworks Holdings (DNA) reported revenue of $27.7M for the third quarter 2026 (Q3 2026), -6% from a year earlier and +37% from the quarter before.
Was Ginkgo Bioworks Holdings profitable in the third quarter 2026?
Operating loss was $43.6M (-157.5% of revenue) and net loss $41.0M.